• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低剂量凝血酶原复合物浓缩物治疗 INR 小于 2.0 的华法林相关性颅内出血。

Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.

机构信息

Department of Pharmacy, Maine Medical Center, 22 Bramhall St, Portland, ME, 04102, USA.

Division of Neurocritical Care, Maine Medical Center, Portland, ME, USA.

出版信息

Neurocrit Care. 2017 Dec;27(3):334-340. doi: 10.1007/s12028-017-0422-7.

DOI:10.1007/s12028-017-0422-7
PMID:28660341
Abstract

BACKGROUND

Prothrombin complex concentrates (PCCs) have become the first-line therapy for warfarin reversal in the setting of central nervous system (CNS) hemorrhage. Randomized, controlled studies comparing agents for warfarin reversal excluded patients with international normalized ratio (INR) <2, yet INR values of 1.6-1.9 are also associated with poor outcomes.

METHODS

We retrospectively reviewed our use of a low-dose (15 units/kg) strategy of 4-factor PCC (4F-PCC) on warfarin reversal (INR 1.6-1.9) in the setting of both traumatic and spontaneous intracranial bleeding.

RESULTS

A total of 21/134 (15.7%) patients with either spontaneous or traumatic intracranial hemorrhage presented with an INR value of 1.6-1.9. Nine patients (43%) presented with traumatic bleeding and 12 (57%) with spontaneous bleeding. The median (IQR) presenting INR was 1.8 (1.7, 1.9) which decreased to 1.3 (1.2, 1.3) following the administration of low-dose 4F-PCC (median dose = 1062 units; 15.2 units/kg). A total of 19/20 (95%) patients achieved a goal INR value of ≤1.5 on the first check following dosing and 17/20 (85%) achieved an INR value ≤1.3. One patient did not have follow-up INR testing due to withdrawal of life support. No patient experienced hematoma expansion within 48 h of 4F-PCC, and there were no thromboembolic events within 72 h of administration.

CONCLUSIONS

The administration of low dose (15 units/kg) of 4F-PCC for urgent warfarin reversal in the setting of CNS hemorrhage was effective in correcting the INR in patients presenting with INR values of 1.6-1.9. Further assessment of low-dose PCC for urgent reversal of modest INR elevation is warranted.

摘要

背景

在中枢神经系统(CNS)出血的情况下,凝血酶原复合物浓缩物(PCC)已成为华法林逆转的一线治疗方法。比较华法林逆转药物的随机对照研究排除了 INR<2 的患者,然而 INR 值为 1.6-1.9 也与不良结局相关。

方法

我们回顾性地回顾了我们在创伤性和自发性颅内出血的情况下使用低剂量(15 单位/公斤)4 因子 PCC(4F-PCC)策略对 INR 为 1.6-1.9 的华法林逆转的使用情况。

结果

共有 21/134(15.7%)自发性或创伤性颅内出血患者的 INR 值为 1.6-1.9。9 例(43%)患者为创伤性出血,12 例(57%)为自发性出血。INR 的中位数(IQR)为 1.8(1.7,1.9),使用低剂量 4F-PCC 后降至 1.3(1.2,1.3)(中位数剂量=1062 单位;15.2 单位/公斤)。20 例患者中有 19 例(95%)在给药后第一次检查时达到 INR 值≤1.5,17 例(85%)达到 INR 值≤1.3。1 例患者因停止生命支持而未进行后续 INR 检测。在使用 4F-PCC 后 48 小时内,没有患者发生血肿扩大,在给药后 72 小时内没有发生血栓栓塞事件。

结论

在 CNS 出血的情况下,为紧急华法林逆转而给予低剂量(15 单位/公斤)的 4F-PCC 可有效纠正 INR 值为 1.6-1.9 的患者的 INR。需要进一步评估低剂量 PCC 对中度 INR 升高的紧急逆转作用。

相似文献

1
Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.低剂量凝血酶原复合物浓缩物治疗 INR 小于 2.0 的华法林相关性颅内出血。
Neurocrit Care. 2017 Dec;27(3):334-340. doi: 10.1007/s12028-017-0422-7.
2
Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.四因子凝血酶原复合物浓缩剂用于脑出血患者亚治疗性国际标准化比值时华法林逆转的安全性和有效性
Neurocrit Care. 2016 Dec;25(3):359-364. doi: 10.1007/s12028-016-0271-9.
3
Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.在一家三级学术医疗中心比较四因子凝血酶原复合物浓缩剂与三因子凝血酶原复合物浓缩剂对华法林的逆转效果评估。
J Emerg Med. 2016 Jan;50(1):7-13. doi: 10.1016/j.jemermed.2015.07.024.
4
Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.凝血酶原复合物浓缩剂用于逆转颅内出血患者华法林所致的凝血病。
Clin Neurol Neurosurg. 2013 Jun;115(6):770-4. doi: 10.1016/j.clineuro.2012.07.006. Epub 2012 Jul 24.
5
Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.四种因子凝血酶原复合物固定剂量、基于体重给药逆转华法林抗凝的疗效和安全性。
Hematology. 2020 Dec;25(1):489-493. doi: 10.1080/16078454.2020.1855745.
6
Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.用于危及生命的出血或急诊手术的四因子凝血酶原复合物浓缩剂:一项回顾性评估。
J Crit Care. 2016 Dec;36:166-172. doi: 10.1016/j.jcrc.2016.06.024. Epub 2016 Jul 5.
7
Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.四因子凝血酶原复合物浓缩剂给药时机和剂量对华法林相关颅内出血结局的影响
Pharmacotherapy. 2022 May;42(5):366-374. doi: 10.1002/phar.2680. Epub 2022 Apr 28.
8
High versus low fixed-dose four factor-prothrombin complex concentrate for warfarin reversal in patients with intracranial hemorrhage.高剂量与低剂量固定剂量四因子凝血酶原复合物浓缩物治疗颅内出血患者华法林逆转。
Transfus Apher Sci. 2022 Oct;61(5):103444. doi: 10.1016/j.transci.2022.103444. Epub 2022 Apr 6.
9
Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII.华法林相关颅内出血的治疗:凝血酶原复合物浓缩物与重组活化因子 VII 的比较。
World Neurosurg. 2010 Dec;74(6):631-5. doi: 10.1016/j.wneu.2010.06.030.
10
Impact of a Pharmacist-Driven Prothrombin Complex Concentrate Protocol on Time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage.一项药师主导的凝血酶原复合物浓缩物给药方案对接受华法林相关性颅内出血患者给药时间的影响。
West J Emerg Med. 2018 Sep;19(5):849-854. doi: 10.5811/westjem.2018.6.37932. Epub 2018 Aug 13.

引用本文的文献

1
Safety and Effectiveness of Four-Factor Prothrombin Complex Concentrate in Special Populations with INR Below 2: A Post-Marketing Surveillance Study.四因子凝血酶原复合物浓缩剂在国际标准化比值低于2的特殊人群中的安全性和有效性:一项上市后监测研究
Cardiol Ther. 2024 Sep;13(3):603-614. doi: 10.1007/s40119-024-00380-7. Epub 2024 Aug 3.
2
Real-World Safety and Effectiveness of a 4-Factor Prothrombin Complex Concentrate in Japanese Patients Experiencing Major Bleeding: A Post-marketing Surveillance Study.四因子凝血酶原复合物浓缩剂在日本大出血患者中的真实世界安全性和有效性:一项上市后监测研究。
Cardiol Ther. 2024 Mar;13(1):221-232. doi: 10.1007/s40119-024-00357-6. Epub 2024 Feb 6.
3

本文引用的文献

1
Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial.新鲜冷冻血浆与凝血酶原复合物浓缩物治疗维生素 K 拮抗剂相关颅内出血患者(INCH):一项随机试验。
Lancet Neurol. 2016 May;15(6):566-73. doi: 10.1016/S1474-4422(16)00110-1. Epub 2016 Apr 11.
2
Comparison of Intracerebral Hemorrhage Volume Calculation Methods and Their Impact on Scoring Tools.脑出血体积计算方法的比较及其对评分工具的影响。
J Neuroimaging. 2017 Jan;27(1):144-148. doi: 10.1111/jon.12370. Epub 2016 Jun 14.
3
Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.
《日本循环学会/日本心律学会2020年心律失常药物治疗指南》
J Arrhythm. 2022 Oct 25;38(6):833-973. doi: 10.1002/joa3.12714. eCollection 2022 Dec.
4
Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2.应用药代动力学模型探索 INR<2 时的华法林逆转患者 4F-PCC 的给药方案。
Blood Adv. 2020 Sep 8;4(17):4208-4216. doi: 10.1182/bloodadvances.2020002267.
5
Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.低剂量与制造商推荐剂量四因子凝血酶原复合物浓缩物用于急性华法林逆转的比较。
J Thromb Thrombolysis. 2019 Feb;47(2):263-271. doi: 10.1007/s11239-018-1768-1.
四因子凝血酶原复合物浓缩剂用于脑出血患者亚治疗性国际标准化比值时华法林逆转的安全性和有效性
Neurocrit Care. 2016 Dec;25(3):359-364. doi: 10.1007/s12028-016-0271-9.
4
Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis.维生素K拮抗剂相关颅内出血中凝血酶原复合物浓缩剂的固定剂量与可变剂量:一项回顾性分析
Neurocrit Care. 2017 Feb;26(1):64-69. doi: 10.1007/s12028-016-0248-8.
5
Thrombotic complications following the administration of high-dose prothrombin complex concentrate for acute warfarin reversal.高剂量凝血酶原复合物浓缩剂用于急性华法林逆转后的血栓形成并发症
Am J Emerg Med. 2016 Aug;34(8):1736.e1-3. doi: 10.1016/j.ajem.2015.12.069. Epub 2015 Dec 28.
6
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.颅内出血中抗栓药物逆转指南:神经重症监护学会和危重症医学会给医疗保健专业人员的声明
Neurocrit Care. 2016 Feb;24(1):6-46. doi: 10.1007/s12028-015-0222-x.
7
Thromboembolic Events After Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate: Exploratory Analyses of Two Randomized, Plasma-Controlled Studies.使用四因子凝血酶原复合物浓缩物逆转维生素K拮抗剂后的血栓栓塞事件:两项随机、血浆对照研究的探索性分析
Ann Emerg Med. 2016 Jan;67(1):96-105.e5. doi: 10.1016/j.annemergmed.2015.04.036. Epub 2015 Jun 17.
8
Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.抗凝治疗相关脑出血患者的抗凝逆转、血压水平和抗凝恢复。
JAMA. 2015 Feb 24;313(8):824-36. doi: 10.1001/jama.2015.0846.
9
Fulminant intraoperative right heart and pulmonary artery thrombosis following prothrombin complex concentrate infusion after complex open heart surgery with cardiopulmonary bypass.
A A Case Rep. 2014 Apr 15;2(8):89-91. doi: 10.1097/ACC.0b013e3182a070e9.
10
Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage.在创伤性脑损伤和颅内出血中使用4因子凝血酶原复合物浓缩物逆转华法林相关凝血病。
J Clin Neurosci. 2014 Nov;21(11):1881-4. doi: 10.1016/j.jocn.2014.05.001. Epub 2014 Jun 18.